Document Classification

Section Type: METHODS

Text: In part 1 of this trial, undertaken in 67 sites in the USA, Canada, and Europe, 520 treatment-naive patients with genotype 1 hepatitis C virus infection were randomly assigned to receive peginterferon alfa-2b 1. 5 mug/kg plus ribavirin 800-1400 mg daily for 48 weeks (PR48 ; n = 104) ; peginterferon alfa-2b and ribavirin daily for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24 weeks (PR4/PRB24 ; n = 103) or 44 weeks (PR4/PRB44 ; n = 103) ; or peginterferon alfa-2b, ribavirin, and boceprevir three times a day for 28 weeks (PRB28 ; n = 107) or 48 weeks (PRB48 ; n = 103).